[DOI] [PMC free article] [PubMed] [Google Scholar] 22.Chiou HC, Lin MW, Hsiao PJ, Chen CL, Chiao S, Lin TY, Chen YC, Wu DC, Lin MH
Obesity: Identification, Assessment and Management
Across the trials, when people stop the medication, the weight tends to come back, on the order of two-thirds of what was lost within a year
52 In a phase 1b trial done to evaluate the safety, pharmacokinetics and pharmacodynamics of orforglipron in patients with T2DM, orforglipron resulted in significant reductions in HbA1c, fasting blood glucose and body weight, with an adverse event profile consistent with that of other GLP-1RA
Overall, the GLP-1RA group had a 10% decrease in depression risk compared to the DPP4i group